Structured evidence table for Chromium Insulin Sensitivity Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Chromium Insulin Sensitivity Randomized Trial | Chromium supplementation has been associated with encouraging improvements in insulin sensitivity. | 1 | Babakr AT (2026) | Chromium as a Modulator of Insulin Receptor Activity: A Systematic Review of Its Role in Metabolic Syndrome and Type 2 Diabetes. |
| Chromium Insulin Sensitivity Randomized Trial | This comprehensive review delves into the implications of chromium supplementation, particularly chromodulin, in the context of MetS and its associated pathological sequelae. | 1 | Babakr AT (2026) | Chromium as a Modulator of Insulin Receptor Activity: A Systematic Review of Its Role in Metabolic Syndrome and Type 2 Diabetes. |
| Chromium Insulin Sensitivity Randomized Trial | In conclusion, chromium (Cr) enhances insulin sensitivity by directly activating the insulin receptor kinase, which lowers the required insulin concentration for maximal cellular response and improves glucose uptake and storage. | 1 | Babakr AT (2026) | Chromium as a Modulator of Insulin Receptor Activity: A Systematic Review of Its Role in Metabolic Syndrome and Type 2 Diabetes. |
| Chromium Insulin Sensitivity Randomized Trial | Metabolic syndrome (MetS) is a complex interplay of interrelated metabolic derangements, including insulin resistance, dyslipidemia, central adiposity, and hypertension, thereby markedly amplifying the predisposition to type 2 diabetes mellitus (T2DM) and cardiovascular morbidities. | 1 | Babakr AT (2026) | Chromium as a Modulator of Insulin Receptor Activity: A Systematic Review of Its Role in Metabolic Syndrome and Type 2 Diabetes. |
| Chromium Insulin Sensitivity Randomized Trial | While women in developing countries may display lean PCOS phenotypes with severe reproductive dysfunction, women in industrialized countries frequently present with obesity-associated insulin resistance and metabolic syndrome (). | 3 | Natarajan Madhumitha (2026) | Micronutrients in polycystic ovary syndrome: molecular pathways, deficiencies, and therapeutic potential |
| Chromium Insulin Sensitivity Randomized Trial | Given the growing body of evidence linking micronutrient status to PCOS pathophysiology, there is a need to consolidate existing mechanistic and clinical evidence. | 3 | Natarajan Madhumitha (2026) | Micronutrients in polycystic ovary syndrome: molecular pathways, deficiencies, and therapeutic potential |
| Chromium Insulin Sensitivity Randomized Trial | The following sections examine each micronutrient’s molecular targets and clinical relevance, integrating evidence from observational studies and randomized trials with mechanistic data from cellular and animal models to clarify their potential to modulate key pathways underlying insulin resistance, hyperandrogenism, oxidative stress, and inflammation in PCOS. | 3 | Natarajan Madhumitha (2026) | Micronutrients in polycystic ovary syndrome: molecular pathways, deficiencies, and therapeutic potential |
| Chromium Insulin Sensitivity Randomized Trial | 1 2 Polycystic Ovary Syndrome (PCOS) stands as one of the most prevalent endocrine–metabolic conditions affecting women during their reproductive years at a rate of 21% worldwide and varies from 7% to 20% in Indian women based on different diagnostic standards. | 3 | Natarajan Madhumitha (2026) | Micronutrients in polycystic ovary syndrome: molecular pathways, deficiencies, and therapeutic potential |
Source documents